Loading...
Immunotherapies & Innovations for Infectious Diseases Congress 2019

December 4 & 5 LYON - ENS

News Twitter

Program

Day 1

Wednesday 4 December 2019

8h00

Registration & welcome coffee

8h45

Welcome address

9h00

Opening

OPENING LECTURE
SANOFI Serge WEINBERG

Serge WEINBERG
Chairman of the Board of Directors
SANOFI

9h15

KEYNOTE LECTURES

Anti-staphylococcal mAbs clinical programms : are we close from success ?
CHU Limoges Bruno François

Bruno François
Specialist in Intensive Care medicine and Anesthesiology
University Hospital of Limoges, France

Recent Developments and Results on human Correlates in tuberculosis
Leiden University Medical Centre Thomas HM Ottenhoff

Thomas HM Ottenhoff
Professor in Immunology, and Head of the Infectious Disease Laboratory
Leiden University Medical Center, Netherlands

10h45

Coffee Break at Exhibition Hall I Partnering (B2B Meetings)

11h15

KEYNOTE LECTURES

The current knowledge of resistance in Mycobacterium tuberculosis
University of Oxford Derrick Crook MBBCh, FRCP, FRCPath

Derrick Crook MBBCh, FRCP, FRCPath
Professor of Microbiology
Nuffield Department of Medicine, University of Oxford and Infectious Diseases Physician, Oxford University Hospitals NHS Trust, UK

12h00

Lunch at Exhibition Hall I Partnering (B2B Meetings)

13h00

Poster Presentation at Exhibition Hall I Partnering (B2B Meetings)

14h00

Track 1 – Innovative therapeutic approaches to fight infectious diseases

Session I – New Therapeutic approaches to fight infectious diseases

Phage therapy in patients with complex bone and joint infection
Hospices Civils de Lyon Tristan Ferry

Tristan Ferry
Deputy Head of Department, Coordinator of the CRIOAc of Lyon
Infectious and Tropical Diseases Service
Hôpital de la Croix-Rousse
Hospices Civils de Lyon, France

Phages : current evidence and future perspectives
Clinique de la Muette Patrick Jault

Patrick Jault
Specialist in Intensive Care medicine and Anesthesiology
Clinique de la Muette, France

Hookipa Pharma Daniel D. Pinschewer

Daniel D. Pinschewer
Chief Scientific Officer
Hookipa Pharma Inc., USA

Track 2 – Detection, Diagnosis & Biomarkers – Fast, efficient and robust new strategies

Session I – Diagnosis & biomarkers: where we are?

Molecular signature of Flu vaccine responsiveness in elderly singaporeans
SANOFI PASTEUR Laurence Quemeneur

Laurence Quemeneur
Senior Scientist Human Immunology R&D
SANOFI PASTEUR, France

A Universal Pathogenome Assay for NGS-based Drug Response Detection
Ares Genetics GmbH Andreas Posch

Andreas Posch
CEO
Ares Genetics GmbH, Austria

Single cell phenotyping for ultra-rapid AST using Captiver AST System
Astrego Diagnostics Özden Baltekin

Özden Baltekin
CSO
Astrego Diagnostics, Sweden

15h30

Coffee Break at Exhibition Hall I Partnering (B2B Meetings)

16h30

Track 1 – Innovative therapeutic approaches to fight infectious diseases

Session Pitch – New approaches and innovative projects

Memory of innate immunity as a target for adjuvants discovery
Boehringer Ingelheim Karelle De Luca

Karelle De Luca
Head of Immunology and Antigen Design
Boehringer Ingelheim, France

Engineering bacteriophages for sequence-specific removal of pathogenic bacterial strains
Eligo Bioscience Xavier Duportet

Xavier Duportet
Co-founder & CEO
Eligo Bioscience, France

Odilorhabdins: a new class of antibiotics against Gram-negative pathogens
Nosopharm Philippe Villain-Guilot

Philippe Villain-Guillot
CEO & Founder
Nosopharm, France

Nasal nanovaccine for toxoplasmosis
Vaxinano Dider Betbeder

Didier Betbeder
Founder & CSO
Vaxinano

An innovative repurposing strategy to rapidly unleash antimicrobial therapeutics
Signia Therapeutics Mario Andrés Pizzorno

Mario Andrés Pizzorno
Co-founder & Project Manager
Signia Therapeutics, France

Track 2 – Detection, Diagnosis & Biomarkers – Fast, efficient and robust new strategies

Session Pitch – New technologies and innovative approaches

Sepsis syndromic diagnosis: 105plex for bacteria and resistances straightforward characterization
Axoscience Laëtitia Villiers

Laëtitia Villiers
CIFRE PhD Researcher
Axoscience, France

Strategy for combating bacterial chronic infections: the Antibiofilmogram®
Biofilm Control Jason Tasse

Jason Tasse
Clinical Research Project Manager
Biofilm Control, France

Diagnostics based on enzyme turnover with molecular probes showing innovative signal retention
Molsid Jens Hasserodt

Jens Hasserodt
Co-founder and Chief Scientific Adviser
Molsid, France

A True Near-Patient Diagnostic solution
miDiagnostics Marijke Van der Auwera

Marijke Van der Auwera
Director Strategic Marketing
miDiagnostics, Belgium

Machine Learning based identification of biomarkers from cytometry data
Altrabio Pierre-Emmanuel Jouve

Pierre-Emmanuel Jouve
Computer Sciences - Machine Learning
Altrabio, France

Increased Throughput and Reduced Variability of Virus Plaque Assays with Automated Imaging and Analysis
PerkinElmer Delphine Coiffier

Delphine Coiffier
Reagent & Plate Reader Sales Rep
PerkinElmer

18h00

End of DAY 1

19h30

Cocktail Diner - Pistache, 8 Quai Claude Bernard, 69007 Lyon

Day 2

Thursday 5 December 2019

8h30

Welcome Coffee

09h00

Track 1 – Innovative therapeutic approaches to fight infectious diseases

Session II – Next Generation of antimicrobials against infectious diseases

Building a European Laboratory Network for Anti-infective Clinical Trials – COMBACTE LAB-Net: 6 Years in
University of Antwerp Tomislav Kostyanev

Tomislav Kostyanev
Clinical Microbiologist
COMBACTE LAB-Net
University of Antwerp, Belgium

Control of viral infections by epigenetic-targeted therapy
University of Franche-Comté Georges Herbein

Georges Herbein
Professor of Medical Virology and Head of the Department of Pathogens & Inflammation
University of Franche-Comté, France

Mining and building from antimicrobial diversity, new ways of screening to obtain new scaffolds
Evotec Jens Glaeser

Jens Glaeser
Principal Scientist
Evotec, Germany

Track 2 – Detection, Diagnosis & Biomarkers – Fast, efficient and robust new strategies

Session II – New tools for faster and efficient diagnostics

Rapid Microbiological Diagnostics : Requirements and Reality?
BioMérieux Alex Van Belkum

Alex Van Belkum
Scientific Director of Microbiology
BioMérieux, France

From sample to answer: Fully automated rapid phenotypic AST
Q-linea Mats Gulberg

Mats Gulberg
VP IP & Research
Q-linea, Sweden

Bringing Syndromic molecular diagnostic to routine use
Mobidiag Yann Marcy

Yann Marcy
President Mobidiag France
R&D Director, Platform Development
Mobidiag, France/Finland

10h30

Coffee Break at Exhibition Hall I Partnering (B2B Meetings)

11h00

Track 1 – Innovative therapeutic approaches to fight infectious diseases

Session III – Microbiome modulation to fight infectious diseases

MAIT cells and microbiota
Eligo Bioscience Olivier Lantz

Olivier Lantz
Director of the Clinical Immunology Laboratory
Institut Curie, France

Microbiome therapeutics: learnings from clinical studies of C. difficile infection
Seres Therapeutics Kevin Litcofsky

Kevin Litcofsky
Director, Molecular Technologies
Seres Therapeutics, USA

Track 3 – Monitoring, Epidemiology & Control – Management & follow-up of infectious diseases

Session I – Preventing the rise of antimicrobial resistance

The epidemiology of tuberculosis (TB), mechanisms & spread of resistance of Mtb
Forschungszentrum Borstel Christian Utpate

Christian Utpate
Researcher
Forschungszentrum Borstel, Germany

Real-time visualization of drug resistance acquisition by horizontal gene transfer reveals a new role for AcrAB-TolC multidrug efflux pump
Institut de Biologie et Chimie des Protéines (IBCP) Christian Lesterlin

Christian Lesterlin
Research & Group Leader
University of Lyon
Institut de Biologie et Chimie des Protéines (IBCP), France

12h00

Lunch at Exhibition Hall I Partnering (B2B Meetings)

13h00

Poster Presentation at Exhibition Hall I Partnering (B2B Meetings)

14h00

Track 1 – Innovative therapeutic approaches to fight infectious diseases

Session IV - Immunotherapy to treat infectious diseases

Antibody-mediated immunomodulation
Institute for Regenerative Medicine & Biotherapy Mireia Pelegrin

Mireia Pelegrin
CNRS Researcher, Group leader of “Antibodies and Immunomodulation”
Institute for Regenerative Medicine & Biotherapy, France

TORC1 inhibition with RTB101 as a potential immunotherapy to decrease the incidence of illness associated with respiratory tract infections in older adults
resTORbio William Marshall

William Marshall
VP of Medical Sciences
resTORbio, USA

Challenges in Exosome Isolation and Characterization in Health and Disease
University of Pittsburgh School of Medicine Theresa Whiteside

Theresa Whiteside
Professor of Pathology, Immunology and Otolaryngology
University of Pittsburgh School of Medicine, USA

Track 3 – Monitoring, Epidemiology & Control – Management & follow-up of infectious diseases

Session II – Artificial Intelligence & Big Data Management on Epidemiology

Transmission of antibiotic resistant microbes in diverse habitats
Barnes Jewish Hospital Carey-Ann Burnham

Carey-Ann Burnham
Professor of Pathology & Immunology, Molecular Microbiology, Medicine, and Pediatrics
Washington University in St. Louis School of Medicine in St. Louis, Missouri, USA
Medical director of clinical microbiology
Barnes Jewish Hospital, USA

Promises and limits of big data analytics to track antimicrobial resistant bacteria in hospital networks
CIRI Jean-Philippe Rasigade

Jean-Philippe Rasigade
Clinical microbiologist, Researcher & Medical Teacher
Centre International de Recherche en Infectiologie (CIRI)
University of Lyon, France

Leveraging next-generation sequencing for the microbiological diagnostic: introducing clinical metagenomics
University of Paris and the Bichat-Claude Bernard University teaching Hospital in Paris Etienne Ruppé

Etienne Ruppé
Associate Professor of Bacteriology
University of Paris and the Bichat-Claude Bernard University teaching Hospital in Paris, France

15h30

Coffee Break at Exhibition Hall I Partnering (B2B Meetings)

16h00

CLOSING KEYNOTES

How microbiome science is bringing opportunities to fight infectious and chronic diseases
INRA Joël Doré

Joël Doré
Scientific Director
MetaGenoPolis
Research Director
INRA, France

To borrow or to innovate ? How treatments in infectious diseases benefit from innovations for patients with cancer
Fundação Champalimaud Markus Maeurer

Markus Maeurer
Head of the Champalimaud Immunotherapy Programme
Fundação Champalimaud, Portugal

17h00

Prix for the Best Poster - Announcement of I4ID2020

17h30

End of Congress

ORGANIZERS